Kapadi Sp. z o.o
Kapadi Sp. z o.o is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI)
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination with Glofitamab in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
An open-label, phase I/II multicenter clinical trial of NECVAX-NEO1 as add-on to first-line neoadjuvant anti-PD-1 monoclonal antibody therapy in patients with triple-negative breast cancer
Sponsor NEC Bio Therapeutics GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Sponsor Silence Therapeutics PLC
- Start (EU)
- Latest update
- Estimated end
An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR).
Sponsor Polish Myeloma Consortium
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
Sponsor Polish Myeloma Consortium
- Start (EU)
- Latest update
- Estimated end
A prospective, multicenter, phase II trial to assess the efficacy and safety of MRD-driven treatment with VEnetoclax and RItuximab combination in previously unTreated pAtients with chronic lymphocytic leukemia (VERITA PALG-CLL5 study)
Sponsor Polish Adult Leukemia Group
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Kapadi Sp. z o.o?
The 2026-10-09 snapshot links Kapadi Sp. z o.o to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Data management, Electronic data capture, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Kapadi Sp. z o.o?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Kapadi Sp. z o.o conducted?
The linked trials record locations in 15 countries, including Poland, Germany, Spain, Italy, Finland. These are trial locations, not confirmed office locations or countries where Kapadi Sp. z o.o delivered services.
What can this page tell me about Kapadi Sp. z o.o's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Kapadi Sp. z o.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Kapadi Sp. z o.o.